Skip to main content

Table 2 Multivariable regression model of predictors for changes in liver attenuation and liver enzymes

From: Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

  Overall (n = 81)
Liver attenuation (HU) p
Single agent therapy -5.54 (-10.64, -0.44) 0.034*
Obesity (BMI ≥ 30) 1.57 (-5.93, 2.79) 0.475
Baseline steatosis/steatohepatitis 1.38 (-5.93, 2.79) 0.692
Steroid use -1.50 (-6.06, 3.06) 0.514
Baseline liver attenuation -0.42 (-0.68, -0.16) 0.002*
Age 0.06 (-0.10, 0.22) 0.459
Gender 1.56 (-2.95, 6.07) 0.493
  Overall (n = 81)
Liver enzymes (AST) p
Single agent therapy 1.49 (-1.74, 4.72) 0.360
Obesity (BMI ≥ 30) -0.23 (-3.01, 2.55) 0.871
Baseline steatosis/steatohepatitis 1.64 (-2.54. 5.82) 0.436
Steroid use -3.21 (-6.08, -0.33) 0.030*
Baseline AST -0.79 (-0.90, -0.68) 0.000*
Age -0.03 (-0.13, 0.08) 0.633
Gender 0.64 (-2.23, 3.51) 0.659
  Overall (n = 81)
Liver enzymes (ALT) p
Single agent therapy 6.46 (-0.77, 13.69) 0.079
Obesity (BMI ≥ 30) 2.86 (-3.29, 9.00) 0.358
Baseline steatosis/steatohepatitis 6.85 (-2.50, 16.20) 0.148
Steroid use -1.36 (-7.72, 5.01) 0.673
Baseline ALT -0.79 (-0.90, -0.67) 0.000*
Age -0.20 (-0.44, 0.03) 0.091
Gender 4.51 (-1.88, 10.91) 0.164
  1. Note. Data are presented as mean change with the associated 95% confidence interval
  2. HU Hounsfield unit